RT @HowardTLeeMD: @Nephro_Sparks @AtoosaRabiee @GiJournal @NEJM @8pm @ggarciatsao @JuanAbraldes There are two prior #metaanalyses showed th…
RT @HowardTLeeMD: @Nephro_Sparks @AtoosaRabiee @GiJournal @NEJM @8pm @ggarciatsao @JuanAbraldes There are two prior #metaanalyses showed th…
RT @HowardTLeeMD: @Nephro_Sparks @AtoosaRabiee @GiJournal @NEJM @8pm @ggarciatsao @JuanAbraldes There are two prior #metaanalyses showed th…
@Nephro_Sparks @AtoosaRabiee @GiJournal @NEJM @8pm @ggarciatsao @JuanAbraldes There are two prior #metaanalyses showed there were short term survival benefit of #gijc 📚https://t.co/vLmIJhWyOS 📚https://t.co/6tuvKmoy7w
RT @rrosenblattmd: A @cochranecollab @CochraneLibrary review noted the potential benefits of terlipressin while acknowledging its adverse e…
RT @rrosenblattmd: A @cochranecollab @CochraneLibrary review noted the potential benefits of terlipressin while acknowledging its adverse e…
A @cochranecollab @CochraneLibrary review noted the potential benefits of terlipressin while acknowledging its adverse effects as well. https://t.co/EZU49UyAd4 https://t.co/KoKQR6FwdE
Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. https://t.co/beUIvcTfjK
New NNT→Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. https://t.co/E0z5dLbNLX
terlipressin may be associated with beneficial effects on mortality and renal function in people with cirrhosis and type 1 hepatorenal syndrome, but it is also associated with serious adverse effects. Then we need better RCTs/ ther…https://t.co/F9rTDuKmDz
New NNT→Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. https://t.co/E0z5dLbNLX